April 10, 2017
Akers Biosciences to market Heparin PF4 rapid test in Puerto Rico
Akers Biosciences, a developer of rapid health information technologies, has begun marketing its rapid test for heparin-induced thrombocytopenia (“HIT”) to the large number of hospital facilities in Puerto Rico as an extension of the company’s strategy to accelerate U.S. sales of its flagship product.